MYCIO Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

MYCIO Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,200	Closed	-$105K	–	650
2016 Q3	$105K	Sell	1,200 -18	-1%	-$1.7K	0.02%	252
2016 Q2	$105K	Buy	1,218 +18	+2%	+$1.55K	0.02%	256
2016 Q1	$95K	Hold	1,200	–	–	0.02%	245
2015 Q4	$151K	Sell	1,200 -9	-0.7%	-$1.09K	0.03%	172
2015 Q3	$126K	Buy	1,209 +209	+21%	+$26.9K	0.03%	180
2015 Q2	$123K	Hold	1,000	–	–	0.02%	187
2015 Q1	$118K	Buy	+1,000	New	+$120K	0.02%	192
2014 Q3	–	Sell	-300	Closed	-$28K	–	658
2014 Q2	$28K	Hold	300	–	–	0.01%	344
2014 Q1	$21K	Hold	300	–	–	0.01%	381
2013 Q4	$22K	Buy	+300	New	+$20.9K	0.01%	357

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MYCIO Wealth Partners's VRTX Position: Q4 2016 in Review

MYCIO Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 1,200 shares — an estimated $105K sold.

MYCIO Wealth Partners first reported a position in VRTX in Q4 2013 and held it in 10 quarters. The position peaked at $151K in Q4 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

MYCIO Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
MYCIO Wealth Partners sold 1,200 Vertex Pharmaceuticals shares in Q4 2016, an estimated $105K.
MYCIO Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 10 quarters.
MYCIO Wealth Partners's Vertex Pharmaceuticals position peaked at $151K in Q4 2015.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on MYCIO Wealth Partners's 13F filing for Q4 2016, filed 1 Feb 2017.